SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study
Linda Veith Sanches,Stephan Greten,Johanna Doll-Lee,Sophia Rogozinski,Johanne Heine,Lea Krey,Sarana Ulaganathan,Ida Jensen,Matthias Höllerhage,Sam Sani,Günter Höglinger,Florian Wegner,Martin Klietz
DOI: https://doi.org/10.2147/ndt.s474584
IF: 2.989
2024-10-01
Neuropsychiatric Disease and Treatment
Abstract:Linda Veith Sanches, 1, &ast Stephan Greten, 1, &ast Johanna Doll-Lee, 1 Sophia Marie Rogozinski, 1 Johanne Heine, 1 Lea Krey, 1 Sarana Ulaganathan, 1 Ida Jensen, 1, 2 Matthias Höllerhage, 1 Sam Sadeghi Sani, 1 Günter U Höglinger, 1– 4 Florian Wegner, 1 Martin Klietz 1 1 Department of Neurology, Hannover Medical School, Hannover, Germany; 2 Department of Neurology, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany; 3 Munich Cluster for Systems Neurology, SyNergy, Munich, Germany; 4 German Center for Neurodegenerative Diseases, DZNE, Munich, Germany &astThese authors contributed equally to this work Correspondence: Stephan Greten, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany, Tel +49 511 532-6462, Fax +49 511 532-6677, Email Introduction: Neuropsychiatric symptoms in particular impair health-related quality of life (QoL) of patients with Parkinson's disease and atypical Parkinsonian syndromes. For this reason, various scales have been developed for detection of neuropsychiatric symptoms, such as the Scale for evaluation of neuropsychiatric disorders in Parkinson's disease (SEND-PD). Objective: First, the objective of this study was to explore the interrelation between the SEND-PD and clinical parameters in patients with Parkinson's disease and thus confirm its validity. In addition, the applicability in a well-defined cohort of patients with atypical Parkinsonian syndromes was investigated for the very first time. Methods: A clinically well-defined cohort of 122 patients with Parkinson's disease (PD), 55 patients with Progressive Supranuclear Palsy (PSP) and 33 patients with Multiple System Atrophy (MSA) were analyzed. First, the SEND-PD was correlated with established disease-specific scores in patients with PD. Next, the results of the SEND-PD were compared between the different Parkinsonian syndromes. Results: The SEND-PD showed a strong significant correlation with several scores, especially the UPDRS I (Rho = 0.655) and GDS-15 (Rho = 0.645). Depressive burden was significantly higher in MSA patients in comparison to the PD patient cohort (PD, 3.8 ± 3.3; MSA, 5.45 ± 3.87), while PSP patients showed significantly less psychotic (PD 1.6 ± 2.1; PSP 0.6 ± 0.9) and impulse control disorders (PD 0.3 ± 1.0; PSP 0.02 ± 0.1). Conclusion: The SEND-PD is a useful, brief and highly applicable screening tool for neuropsychiatric symptoms in PD, but not in atypical Parkinsonism, as their unique neuropsychiatric symptom composition is not fully captured. Keywords: neuropsychiatric symptoms, SEND-PD, Parkinsonian syndromes Parkinson's disease (PD), the second most common neurodegenerative disease, has an increasing incidence and prevalence between 1990 and 2019, up to a current prevalence of around 106/100,000. 1,2 In particular, the number of patients with PD in the older population over the age of 65 grew considerably. 2 PD is associated with increasing rates of disability, reduced quality of life, caregiver burden and huge economic costs. 1,3,4 Beside typical motor symptoms, there is a large entity of non-motor symptoms (NMS) causing considerable disability. 5 Common NMS are pain, hyposmia, rapid eye movement sleep disorders, autonomic dysfunction (such as constipation, drooling of saliva, orthostatic hypotension), cognitive and neuropsychiatric symptoms (NPS). 6,7 The latter include in particular anxiety, depression, cognitive decline, psychosis and apathy. 8 Atypical forms of Parkinsonism, such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP), are considerably rarer than PD, with a prevalence of between 3–5/100,000. 9 The growing incidence of these diseases could be due to the greatly revised and improved diagnostic criteria. 9–11 Atypical Parkinsonian syndromes show a faster disease progression than PD with an average disease duration of seven to ten years. 9,12,13 Similar to PD, symptoms of MSA and PSP are not limited to motor features. In PSP patients, bradyphrenia, apathy, personality changes and fronto-executive dysfunction are common NPS. In contrast, anxiety and depression seem to be the major neuropsychiatric symptoms in MSA. 14 Therefore, it is an essential need to address and treat NPS early at all stages of these diseases as part of a holistic patient management in all cases of Parkinsonism. Clinical tools are commonly applied to assess the typical neuropsychiatric symptoms of Parkinsonian syndrom -Abstract Truncated-
psychiatry,clinical neurology